ILMN Stock Recent News

SAN DIEGO , July 18, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ: ILMN) previously announced on June 24, the company will present a Strategy Update on Tuesday, August 13, 2024 starting at 8:00am Pacific Time. The event will feature presentations by members of Illumina's executive team and conclude with a Q&A session.

Illumina (ILMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Life sciences company Illumina Inc. NASDAQ: ILMN stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of GRAIL, LLC NASDAQ: GRAL on June 24, 2024.

Illumina stock (NASDAQ: ILMN) saw a 6% rise on Wednesday, July 10, faring better than its peer — Mettler-Toledo stock – up 1%. The rise in ILMN stock can primarily be attributed to the company's acquisition of Fluent Biosciences to expand its single-cell analysis and multiomics offerings.

SAN DIEGO , July 11, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ:ILMN) previously announced on June 24, the company will issue results for the second quarter 2024 following the close of market on Tuesday, August 6, 2024.  On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Wednesday, Illumina Inc ILMN acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration.

Last month, Illumina Inc ILMN had to let go of Grail Inc. Still, the DNA sequencing company has acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research.

By integrating Fluent's unique technology with Illumina's (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a comprehensive solution for single-cell multiomic analysis.

Accessible, highly scalable single-cell technology  expands Illumina's multiomics capabilities SAN DIEGO , July 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that effective today it has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology.   "The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy," said Steven Barnard, chief technology officer of Illumina.

When discussing biotechnology, many focus on medication based on biochemical compounds and their downstream effects. Yet several branches of medical genetics and therapeutics have begun to find novel ways to treat and prevent diseases through gene editing, protein manipulation and overall DNA repair.